February 5, 2016 – IGBA Files Recommendations for USTR 2016 Special 301 Review.
February 4, 2016 – Geneva, Switzerland – The International Generic and Biosimilar Medicines Association (IGBA) represents companies that are actively engaged in the global manufacturing and trading systems for medicines. We support enhanced cooperation between regulators to foster the global trade in medicines, as well as measures aimed at the elimination of barriers to trade in medicines in order to increase access for patients.
The International Generic and Biosimilar Medicines Association (IGBA), representing member associations from the U.S. (GPhA), Canada (CGPA), Japan (JGA), Jordan (JAPM), Europe (EGA), South Africa (NAPM), and Taiwan (TGPA), as well as associate member associations from Australia (GBMA), Brazil (ProGenericos) and Mexico (AMEGI), thank for the opportunity to share our thoughts on the important topic of non-proprietary naming of biological products, including biosimilar products.
- IGBA Welcomes ICH Reform and Openness For New Members
- IGPA becomes IGBA and chairmanship shifts to South Africa
- Global Pharmaceutical Associations Welcome MEDICRIME Convention, Landmark Tool to Curb Global Medicines Counterfeiting
- Statement by the International Generic Pharmaceutical Alliance (IGPA), Regarding the Trans-Pacific Partnership